Biotech news for Monday, July 6, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Lobro78/iStock via Getty Images Merck has ended development of MK-1167, an oral positive allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor, in phase 2 for the treatment of Alzheimer's disease. The study's page on ClinicalTrials.gov stat…
The Advisory Committee meetings, a key regulatory step in U.S. drug and MedTech approvals, are making a comeback as the Food and Drug Administration seeks to revisit several controversial decisions made under the former commissioner, Marty Makary. This article…
bizoo_n Cantor initiated coverage of Forward Industries ( FWDI ) and Cypherpunk Technologies ( CYPH ) with an Overweight rating. "The next major shift in financial infrastructure is occurring on-chain, with digital assets positioned to capture a growing share…
iQoncept/iStock via Getty Images Short interest data from late June 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in speculative biotech plays like Recursion Pharmaceuticals ( RX…
Short interest data from late June 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in speculative biotech plays like Intellia Therapeutics ( NTLA ) and SELLAS Life Sciences Group (…
Rigel Pharmaceuticals ( RIGL ) announced on Wednesday the appointment of Alison L. Hannah , M.D., to the role of executive vice president and chief medical officer. The company noted that Hannah has resigned from Rigel's Board of Directors, effective July 1, 2…
Abivax SA ( ABVX ) priced an upsized public offering of 6.4M ADSs at $125/ADS, raising ~$800M in gross proceeds. The offering size was increased from the previously announced $600M. The company granted underwriters a 15% option to purchase up to 960,000 additi…
BridgeBio Pharma ( BBIO ) announced on Wednesday that it has entered into an agreement with funds managed by Sixth Street and funds managed by HealthCare Royalty, under which the purchasers have invested up to $1B in newly issued convertible preferred